Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Marsella R et al. | Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. | 2004 | Vet. Dermatol. | pmid:15500481 |
Mauldin EA et al. | Proliferative and necrotizing otitis externa in four cats. | 2007 | Vet. Dermatol. | pmid:17845627 |
Rosenkrantz WS | Pemphigus: current therapy. | 2004 | Vet. Dermatol. | pmid:15030557 |
Olivry T et al. | Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. | 2010 | Vet. Dermatol. | pmid:20456716 |
Kelley LS et al. | Safety and tolerability of 0.1% tacrolimus solution applied to the external ear canals of atopic beagle dogs without otitis. | 2010 | Vet. Dermatol. | pmid:20609208 |
Nell B et al. | The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. | 2005 Jan-Feb | Vet Ophthalmol | pmid:15644099 |
Berdoulay A et al. | Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. | 2005 Jul-Aug | Vet Ophthalmol | pmid:16008701 |
Hafizi S et al. | Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling. | 2004 May-Jun | Vascul. Pharmacol. | pmid:15607500 |
Dissemond J et al. | Successful treatment of stasis dermatitis with topical tacrolimus. | 2004 | VASA | pmid:15623206 |
Woodward RS et al. | The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: tacrolimus versus cyclosporine. | 2011 | Value Health | pmid:21315636 |